Nilotinib.

Abstract

With imatinib still being linked to the breakthrough in CML therapy and probably being the most prescribed drug, second-generation TKIs are increasingly gaining importance. Showing higher response rates while not leading to more adverse events, nilotinib has become an attractive option in the first-line treatment of chronic-phase chronic myeloid leukemia. By reaching deep and long-lasting molecular remissions, discontinuation of TKIs is becoming one of the central topics of future CML therapy. Stopping nilotinib seems safe and provides a stable remission in about half of the eligible patients, though long-term data are still missing.

• Authors: Martin Gresse, Theo D Kim, Philipp le Coutre
• Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (Recent Results Cancer Res) 2018 Vol. 212 Pg. 69-85 ISSN: 0080-0015 [Print] Germany
• PMID: 30069625 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Pyrimidines
• nilotinib

Topics

• Antineoplastic Agents (pharmacology)
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Protein Kinase Inhibitors (pharmacology)
• Pyrimidines (pharmacology)